RxDoctor Payments Data

Alexander Mbakwem, MD

Internal Medicine · Bronx, NYNPI 1780793778

Payments from drug & device makers

$437in general payments, 2019–2025

Across 17 payments — averaging $25.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$133
  • Esperion Therapeutics, Inc.$46
  • Novo Nordisk$38
  • Otsuka America Pharmaceutical, Inc.$26
  • Teva Pharmaceuticals USA, Inc.$25
  • Sunovion Pharmaceuticals Inc.$23
  • plus $147 from 8 others

What the payments were for

  • Food & beverage$42297%
  • Education$153%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$396,118
Medicare patients
539
Services billed
4,274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban649$242,818
JardianceEmpagliflozin134$53,184
OzempicSemaglutide51$52,566
JanuviaSitagliptin Phosphate93$40,583
Abilify MaintenaAripiprazole11$32,026
XifaxanRifaximin23$31,029
TrulicityDulaglutide32$27,373
XareltoRivaroxaban72$26,551
EntrestoSacubitril/Valsartan31$21,910
MounjaroTirzepatide13$21,061
SantylCollagenase Clostridium Hist.14$20,982
ErtapenemErtapenem Sodium40$17,454
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog86$17,316
NuedextaDextromethorphan Hbr/Quinidine20$13,298
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,124

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$15$242,818649 claims
Novo NordiskOzempic$38$52,56651 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$26$32,02611 claims
Johnson & JohnsonXarelto$23$26,55172 claims
NovartisEntresto$15$21,91031 claims
Avanir Pharmaceuticals, Inc.Nuedexta$16$13,29820 claims
Sunovion Pharmaceuticals Inc.Aptiom$23$11,69619 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →